Illustration: Sarah Grillo/Axios
Argenx plans to acquire Forte Biosciences for approximately $2.2 billion, the companies said Monday.
Why it matters: The deal will bolster Argenx's immunology portfolio and follows a strategic investment it made during Forte's $150 million April IPO.
